Dr. Ronald R. Buggage appointed as Chief Scientific Officer of Novagali Pharma
17 March 2011 - 5:47AM
Business Wire
Regulatory News:
Novagali Pharma (Paris:NOVA), a pharmaceutical company that
develops innovative ophthalmic products, today announced the
appointment of Dr. Ronald R. Buggage as Chief Scientific
Officer.
Ronald Buggage is an ophthalmologist by training and has
acquired solid university and industrial experience in strategic
and operational activities related to the ophthalmic pharmaceutical
development and marketing. He is joining Novagali Pharma as Chief
Scientific Officer, and will head all Clinical, Regulatory and
Research & Development activities.
He began his career as Staff Clinician and Director of the
Ocular Immunology and Uveitis Program at the prestigious National
Eye Institute of the National Institutes of Health in
Bethesda, Maryland, where he led numerous clinical trials in
subjects with retinal disease and was responsible for the education
and clinical supervision of ophthalmologists in training.
In 2004, he joined Pfizer’s laboratories, becoming Worldwide
Medical Director for Research & Development. He notably led
strategic plans aimed at strengthening Pfizer’s position in retinal
diseases.
In 2008, Dr Buggage joined the Novartis group. As New Product
Executive Medical Director within the Neuroscience and
Ophthalmology Franchise, he was responsible for defining and
executing the global development strategy for ophthalmic therapies
within the perspective of their commercialisation.
Ronald R. Buggage, appointed Chief Scientific Officer at
Novagali Pharma, states: “I was attracted by Novagali Pharma, the
competence of its teams, the wealth of its already well-advanced
and promising product portfolio and the development potential of
its unique technological platforms. Novagali Pharma is an exciting
company dedicated to improving the life of patients with ophthalmic
diseases through innovation, and I am delighted to now have the
means of contributing to its expansion.”
Jérôme Martinez, Chairman and CEO of Novagali Pharma, concludes:
“We are very proud and very happy that Ronald has chosen to join
Novagali Pharma. His advanced specialised skill and experience in
ophthalmology, in terms of Research, product development strategy
and registering products with the relevant authorities will be
major advantages for the successful development of Novagali
Pharma’s product portfolio.”
About NOVAGALI Pharma (www.novagali.com)
Founded in 2000, Novagali Pharma SA is a pharmaceutical company
that develops ophthalmic innovative products for all segments of
the eye. Thanks to its three proprietary technology platforms, the
Company has an advanced portfolio of highly innovative products,
one of which is already on sale and two of which are undergoing
phase III clinical trials.
In 2009, Frost & Sullivan recognised Novagali with the Award
for Industry Innovation & Advancement of the Year, for its
proprietary emulsion technology platforms, and Siemens awarded the
company the “Health Award” Grand Prix de l’Innovation for
Novasorb®.
In April 2010, Novagali Pharma and its partners in the Vitrena
project obtained €9.4 million in funding from Oséo for this
diabetic retinopathy project. Novagali Pharma carried out a
successful IPO in July 2010 enabling the Company to raise €22
million.
Novagali Pharma is listed on NYSE Euronext
Paris - Compartment CISIN code: FR0010915553 - Ticker: NOVA
This press release contains certain forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. For a
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de
Risques ») section of the Document de Base filed with the AMF,
which is available on the AMF website (http://www.amf-france.org)
or on Novagali Pharma’s website (www.novagali.com).
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to securities of Novagali Pharma in any country.
Novo Nordisk (TG:NOVA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Novo Nordisk (TG:NOVA)
Historical Stock Chart
From Dec 2023 to Dec 2024
